M’s Science Corporation
http://www.m-sci.com/e/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From M’s Science Corporation
Venturing into the Japanese investment market with Mebiopharm
In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and maintain momentum for lead pipeline projects will no doubt sound familiar to the management of any startup looking to commercialize new technology.
Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008
Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.
Mind over matter - partnerships: CNS deals signed over the past five years
Attention deficit hyperactivity disorder (ADHD)
Date
Company
Partner
Deal terms
March 2009
GlaxoSmithKline
Shire
co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US
November 2008
GlaxoSmithKline
Paladin Labs
three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice